<DOC>
	<DOCNO>NCT01590407</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , 3-part study ass safety , tolerability , pharmacokinetics orally administer ALS-002200 healthy volunteer ( HV ) subject chronic hepatitis C ( CHC ) genotype 1 infection . Part 1 ass single ascend dose pharmacokinetics safety HV . Part 2 ass food effect pharmacokinetics HV . Part 3 ass multiple ascend dose pharmacokinetics safety subject CHC genotype 1 infection .</brief_summary>
	<brief_title>First Human Study ALS-002200 ; Single Dose , Food Effect Healthy Volunteers ; Multiple Doses Chronic Hepatitis C Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Subject provide write consent . In investigator 's opinion , subject able understand comply protocol requirement , instruction , protocol state restriction likely complete study plan . Subject good health deem investigator . Creatinine clearance great 50 mL/min ( CockcroftGault ) Male female , 1855 year age HV 1865 year age subject CHC . Body mass index ( BMI ) 1832 kg/m2 inclusive HV 1836 kg/m2 subject CHC , minimum weight 50 kg population . A female eligible participate study non childbearing potential . If male , subject surgically sterile practice specific form birth control . Additional inclusion criterion subject CHC genotype 1 infection : Positive HCV antibody positive HCV RNA screen . Documentation CHC infection great 6 month screen CHC genotype 1 infection screen HCV RNA viral load ≥ 105 ≤108 IU/mL use sensitive quantitative assay . Liver biopsy within two year Fibroscan evaluation within 6 month prior screen clearly excludes cirrhosis . Fibroscan liver stiffness score must &lt; 12 kPa . Absence hepatocellular carcinoma indicate ultrasound scan conduct screening No prior treatment CHC Absence history clinical hepatic decompensation . Laboratory value include : Prothrombin time &lt; 1.5x ULN Platelets &gt; 120,000/mm3 Albumin &gt; 3.5 g/dL , bilirubin &lt; 1.5 mg/dL screening ( subject document Gilbert 's disease allow ) . Serum alanine aminotransferase ( ALT ) concentration &lt; 5 x ULN Alpha Fetoprotein ( AFP ) concentration ≤ ULN . If AFP ≥ ULN , absence hepatic mass must demonstrate ultrasound within screen period . Clinically significant cardiovascular , respiratory , renal , gastrointestinal , hematologic , neurologic , thyroid , uncontrolled medical illness psychiatric disorder . Positive test HAV IgM , HBsAg , HCV Ab ( HV ) , HIV Ab . Abnormal screen laboratory result consider clinically significant investigator . Drug allergy , limited , sulfonamides penicillin , include experience previous trial experimental drug . Participation investigational drug trial receive investigational vaccine within 30 day 5 half life ( whichever longer ) prior study medication . Clinically significant blood loss elective blood donation significant volume . For healthy subject , history regular use tobacco . The subject positive prestudy drug screen . Laboratory abnormality include : Thyroid Stimulating Hormone ( TSH ) &gt; ULN Hematocrit &lt; 34 % White blood cell count &lt; 3,500/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>